Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. Summary
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/24/2022 01/25/2022 01/26/2022 01/27/2022 01/28/2022 Date
3.42(c) 3.446(c) 3.464(c) 3.412(c) 3.374 Last
571 785 405 326 229 682 215 856 66 752 Volume
-9.52% +0.76% +0.52% -1.50% -1.11% Change
More quotes
Estimated financial data (e)
Sales 2021 48,1 M 53,6 M 53,6 M
Net income 2021 -46,1 M -51,4 M -51,4 M
Net cash position 2021 75,9 M 84,5 M 84,5 M
P/E ratio 2021 -4,67x
Yield 2021 -
Sales 2022 69,2 M 77,1 M 77,1 M
Net income 2022 -18,3 M -20,3 M -20,3 M
Net cash position 2022 2,87 M 3,20 M 3,20 M
P/E ratio 2022 -54,6x
Yield 2022 -
Capitalization 271 M 303 M 302 M
EV / Sales 2021 4,06x
EV / Sales 2022 3,88x
Nbr of Employees 212
Free-Float 75,9%
More Financials
Company
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well... 
More about the company
Ratings of Innate Pharma
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about INNATE PHARMA
01/06Innate pharma obtains eur28.7m in non- dilutive financing in the form of state guarante..
AQ
01/05INNATE PHARMA : Obtains Ç28.7m in Non-Dilutive Financing in the Form of State Guaranteed L..
PU
01/05Innate Secures 28.7 Million Euros in State-Guaranteed Loans
MT
01/05Innate Pharma Receives $32.4 Million State-Backed Financing
MT
01/05Innate Pharma S.A. Obtains €28.7 Million in Non-Dilutive Financing in the Form of ..
CI
01/04INNATE PHARMA : to Participate in Upcoming Investor Conferences - Form 6-K
PU
2021Innate Pharma - FIRST PATIENT DOSED IN IPH6101/SAR443579, PHASE 1/2 CLINICAL TRIAL IN V..
AQ
2021INNATE PHARMA : - Form 6-K
PU
2021Innate Pharma Says Partner Sanofi Doses First Patient in Phase 1/2 In-Human Blood Cance..
MT
2021Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial
CI
2021Innate pharma - monalizumab combined with cetuximab and durvalumab demonstrates anti-tu..
AQ
2021Innate Pharma Says Cancer Drugs Combination Shows Anti-Tumor Activity
MT
2021INNATE PHARMA : Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor..
PU
2021Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort
CI
2021INNATE PHARMA : to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress - Form 6..
PU
More news
News in other languages on INNATE PHARMA
01/05INNATE PHARMA : deux PGE pour 28,7 millions d'euros
01/05La baisse cherche à emmerder la hausse
01/05EN DIRECT DES MARCHES : Amundi, Publicis, ADP, Atos, Korian, Toyota, Samsung, BMW, Sony...
01/05INNATE PHARMA : obtention de deux PGE
01/05Innate Pharma reçoit un financement public de 32,4 millions de dollars
More news
Analyst Recommendations on INNATE PHARMA
More recommendations
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,41 €
Average target price 7,83 €
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
HervÚ Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capi. (M$)
INNATE PHARMA-23.29%303
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892